The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | Predictive relapse indicators for myeloma T-cell engagers (PRIME) model
Tarek Mouhieddine, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the development of the predictive relapse indicators for myeloma T-cell engagers (PRIME) model, which aims to predict the outcome of patients with myeloma receiving BCMA- and GPRC5D-targeting T-cell engagers. Dr Mouhieddine highlights that the model uses five clinical variables to predict progression-free survival at various time points. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
